Profusa, Inc. (PFSA): Entry into a Material Definitive Agreement
Profusa, Inc. (PFSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Amendment No. 5 to Securities Purchase Agreement On August 12, 2026, Profusa, Inc., a Delaware corporation (the “Company”), entered into Amendment No. 5 (“Amendment No. 5”) to that certain Securities Purchase Agreement, dated
How this was made
The 30-second read
Why it matters
The filing introduces a new debt instrument with conversion features, modestly increasing leverage and possible dilution, but the amount is small relative to the company's size.
Market read
Primary disclosure of a small financing transaction; limited trading relevance beyond the stock itself.
What to watch
Potential covenant restrictions or future conversion triggers that could affect cash flow.
Background
Profusa, a developer of diagnostic and therapeutic technologies, disclosed a senior secured convertible note to Ascent Partners Fund LLC as part of a financing arrangement.
Ticker impact
Profusa filed an 8‑K reporting issuance of a $714,285 senior secured convertible promissory note priced at $650,000, creating a new debt obligation.
Limited short‑term price movement; potential slight downside if investors view dilution risk.
The financing is disclosed for the first time, but the principal amount is under $1 M, making material impact unlikely.
Market effects
Minimal effect on the broader biotech/diagnostics sector; similar companies may see comparable financing activity.
No significant regional impact.
Limited global relevance; only relevant to investors in Profusa.
Counterpoint
If the note’s conversion terms are favorable, it could provide cheap capital and support upside.
Key entities
- companyProfusa, Inc.
Issuer of the convertible note.
- investorAscent Partners Fund LLC
Holder of the senior secured convertible promissory note.